Navigation Links
Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkin's Lymphoma
Date:3/16/2008

w">http://www.cticseattle.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of Zevalin include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with Zevalin in particular including, without limitation, the potential failure of Zevalin to prove safe and effective in further studies in combination with fludarabine and mitoxantrone for first-line treatment of untreated patients with follicular NHL or to be developed further in this combination for this indication, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing and selling Zevalin, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:

Dan Eramian

T: 206.272.4343

C: 206.854.1200

Susan Callahan

T: 206.272.4472

F: 206.272.4434

E: media@ctiseattle.com

http://www.cticseattle.com/media.htm

Investors Contact:

Leah Grant

T: 206.282.7100

F: 206.272.4434

E: invest@ctiseattle.com

http://www.cticseattle.com/investors.htm


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
2. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
3. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
4. Isolagen, Inc. Completes Enrollment in Isolagen Therapy(TM) Phase II/III Acne Scar Study
5. NanoBio(R) Corporation Completes $30 Million in Equity Funding by Meeting Key Development Milestones
6. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
7. Pharmacopeia Completes Enrollment in Phase 2 Hypertension Study with PS433540 (DARA)
8. MonoSol Rx Completes Thin Film Ondansetron Pilot Bioequivalence Study
9. First Clinical Volumetric Modulated Arc Therapy Treatment Completed With Elekta Synergy(R) S at General Hospital Vienna
10. Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
11. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Investor-Edge has initiated coverage on the following equities: ... (NASDAQ: HZNP ), Endocyte Inc. (NASDAQ: ... and Theravance Inc. (NASDAQ: THRX ). Free research ... . On Tuesday, November 25, 2014, the NASDAQ ... Average edged 0.02% lower, to finish the day at 17,814.94, ...
(Date:11/26/2014)... Nov. 26, 2014  CARsgen, a leader in the ... to treat a variety of cancers, today announced the ... a China -based healthcare private equity ... focused on the development of new therapeutics for liver, ... Cancer Institute and Shanghai Renji Hospital, the company plans ...
(Date:11/26/2014)... CHARLOTTE, N.C. , Nov. 25, 2014  At ... San Antonio this October, KaVo Kerr Group ... Institute Technology Expo, offering attendees the opportunity to see ... to well-respected key opinion leaders deliver lectures on the ... Kerr Group products include the new DEXIS CariVu Caries ...
Breaking Medicine Technology:Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5CARsgen Completes Series A Financing 2KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 2KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 3
(Date:11/27/2014)... Luciana Lagana and her husband Gregory ... feature film that received 9 awards at the 2014 Zed ... It is also an official selection of the 2014 PollyGrind ... cinematic career for James Noel, a young filmmaker who excels ... mystery, filmed in glorious black and white, watching Omadox will ...
(Date:11/27/2014)... November 27, 2014 An inventor from ... embarrassing fact of life, and she wants to lessen ... minutes later, I decided that there needed to be ... said. , Easy to use and producible in design ... a woman’s private areas throughout the day. It avoids ...
(Date:11/27/2014)... (HealthDay News) -- Most babies and young children don,t ... Food and Drug Administration says. Over-the-counter (OTC) cold ... younger than 2 because they could cause serious and ... adults average about three colds a year, but children ... parents might want to give them pain relievers, decongestants ...
(Date:11/27/2014)... 2014 The founders of VIM & VIGR, ... high functioning compression socks, are proud to announce the debut ... innovative Gradient Pressure (TM) knitting technology that is designed to ... VIGR’s commitment to adding flair and style to a product ... caught the eye of a writer at The New ...
(Date:11/27/2014)... OXNARD, CA (PRWEB) November 27, 2014 ... All-on-4™ dental implants procedure will help one person ... rehabilitation. , Dr. Saj Jivraj and Dr. Mamaly Reshad ... Woodland Hills, Calif., have launched a website devoted to ... A section of the website would be devoted to ...
Breaking Medicine News(10 mins):Health News:Luciana Lagana and Gregory Graham Join the Award-Winning Cast of the Black-and-White Experimental Mystery Feature Film Omadox. 2Health News:Luciana Lagana and Gregory Graham Join the Award-Winning Cast of the Black-and-White Experimental Mystery Feature Film Omadox. 3Health News:Steer Clear of Cold Meds for Babies, FDA Advises 2Health News:VIM & VIGR Announces Launch of Men’s Line of Compression Socks 2Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 2Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 3Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 4Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 5
... nifedipine therapy and placebo, researchers say , , WEDNESDAY, Nov. ... used to prevent premature birth when women go into ... at maintaining pregnancy, after the initial spell of preterm ... who conducted the first ever placebo-controlled test of nifedipine ...
... Media coverage of clinical trials does not contain the ... of the coverage received by pharmaceutical and herbal remedy ... Medicine , has revealed that it is rarely possible ... the described research. , Tania Bubela from the University ...
... The American Veterinary Medical,Association (AVMA) Executive Board voted to ... dogs -- ear cropping and tail,docking. , ... AVMA opposes ear cropping and tail,docking of dogs when done ... ear cropping and tail docking from breed standards." , ...
... DRRX ) announced today that management is scheduled to present ... -- 20th Annual Piper Jaffray Health ... -- RBC Capital Markets 2008 ... A live audio webcast of ...
... ingredients can mean healthier eating without the guilt, experts ... A few healthy substitutions in your Thanksgiving recipes can ... sacrificing the taste, says the American Medical Association. ... swapping out a few ingredients with healthier alternatives, you ...
... (Nasdaq: HLTH ) announced today the preliminary results ... of its common stock at a price of $8.80 per ... on November 25, 2008. Based on the preliminary count ... the tender offer, 86,145,082 shares of common stock (including approximately ...
Cached Medicine News:Health News:Drug to Prevent Preterm Labor Shows Little Benefit 2Health News:Misleading media coverage of medicine 2Health News:AVMA Revises Policy on Ear Cropping and Tail Docking 2Health News:DURECT Corporation to Participate in Upcoming Healthcare Conferences 2Health News:Holiday Meals With a Calorie-Conscious Twist 2Health News:HLTH Corporation Announces Preliminary Results of Its Tender Offer 2Health News:HLTH Corporation Announces Preliminary Results of Its Tender Offer 3Health News:HLTH Corporation Announces Preliminary Results of Its Tender Offer 4
Bravo Vacuum Pump Accessories Kit (One canister, one lid, one "O" ring tube, one tubing set)...
The pouch is designed to protect the Digitrapper. The pouch strap can be worn on a belt loop or carried in a shoulder strap or backpack configuration....
... designed using established technology providing a ... ,Working with pH catheters with ... multi-use catheter is used the Hellige ... the skin.,NOTE: ,Medtronic pH measurement systems ...
...
Medicine Products: